Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:40:39 ON 08 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:40:48 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10534631.str





chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-11 2-14 7-13 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 6-9 7-8 8-9
exact bonds :
2-14 5-7 7-13 9-12
isolated ring systems :

containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:41:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7953 TO ITERATE

25.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 153714 TO 164406
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:41:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 157951 TO ITERATE

100.0% PROCESSED 157951 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.02

L3 31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 13:41:29 ON 08 FEB 2007

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

=> s l3 full
L4 6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:510331 CAPLUS
DOCUMENT NUMBER: 143:172810
TITLE: Imidazo[1,5-a]pyridine-3-ylidenes-pyridine derived N-heterocyclic carbene ligands
AUTHOR(S): Burstein, Christian; Lehmann, Christian W.; Glorius, Frank
CORPORATE SOURCE: Max-Planck-Institut fuer Kohlenforschung, Muelheim an der Ruhr, 45470, Germany
SOURCE: Tetrahedron (2005), 61(26), 6207-6217
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:172810
GI



I

AB The ready synthesis of differently substituted 2H-imidazo[1,5-a]pyridin-4-ium bromides, e.g., I, is reported. These salts were precursors for a class of N-heterocyclic carbene ligands. As a consequence of their bicyclic geometry, these ligands are capable of influencing the coordination sphere of a carbene bound metal. The usefulness of these ligands was demonstrated in the palladium-catalyzed Suzuki-Miyaura cross-coupling of sterically hindered aryl chlorides.
IT 861404-07-1P

RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and ligand use of N-(trimethylphenyl)pyridoimidazolium bromides via condensation of pyridinecarboxaldehydes with trimethylaniline followed by cyclocondensation and anion exchange)

RN 861404-07-1 CAPLUS

CN Imidazo[1,5-a]pyridinium, 5-phenyl-2-(2,4,6-trimethylphenyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

IT 861404-18-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ligand use of N-(trimethylphenyl)pyridoimidazolium bromides via condensation of pyridinecarboxaldehydes with trimethylaniline followed by cyclocondensation and anion exchange)

RN 861404-18-4 CAPLUS

CN Imidazo[1,5-a]pyridinium, 5-phenyl-2-(2,4,6-trimethylphenyl)-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 861404-17-3
CMF C22 H21 N2



CM 2

CRN 37181-39-8
CMF C F3 O3 S



IT 861404-12-8P 861404-13-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ligand use of substituted N-(trimethylphenyl)pyridoimidazolium bromides via cross-coupling of N-(trimethylphenyl)bromopyridoimidaz

olium bromide with boronic acid derivs.)
RN 861404-12-8 CAPLUS
CN Imidazo[1,5-a]pyridinium, 5-(9-phenanthrenyl)-2-(2,4,6-trimethylphenyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 861404-13-9 CAPLUS
CN Imidazo[1,5-a]pyridinium, 5-(2,6-dimethoxyphenyl)-2-(2,4,6-trimethylphenyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:453216 CAPLUS
DOCUMENT NUMBER: 141:23532
TITLE: Preparation of imidazo[1,5-a]pyridine derivatives for treatment of aldosterone synthase mediated diseases
INVENTOR(S): Firooznia, Fariborz
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046145	A1	20040603	WO 2003-EP12851	20031117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

CA 2505752	A1	20040603	CA 2003-2505752	20031117
AU 2003292039	A1	20040615	AU 2003-292039	20031117
EP 1565463	A1	20050824	EP 2003-767563	20031117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016306	A	20050927	BR 2003-16306	20031117
CN 1711262	A	20051221	CN 2003-80103505	20031117
JP 2006508970	T	20060316	JP 2004-552632	20031117
US 2006058342	A1	20060316	US 2005-534631	20050831
PRIORITY APPLN. INFO.:			US 2002-427325P	P 20021118
			WO 2003-EP12851	W 20031117

OTHER SOURCE(S): MARPAT 141:23532
GI



I

AB Title compds. I [wherein R 1 = cycloalkyl, heteroalkyl, (un)substituted aryl; R2, R3 = independently H, CF3, alkoxy, or R2R3 = (un)substituted (hetero)aromatic ring; and pharmaceutically acceptable salts thereof] were prepared for the treatment of aldosterone mediated diseases. For example, 5-(naphthalen-1-yl)imidazo[1,5-a]pyridine hydrochloride (II) was prepared in 5 steps synthesis starting from the reaction of 2-(aminomethyl)pyridine with Ph isothiocyanate. II showed activity for inhibition of the aldosterone synthase with an IC50 value of about 50μM. Thus, I and their pharmaceutical compns. are useful for prevention, delay of progression, or the treatment of aldosterone synthase mediated diseases, such as hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, postmyocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction (no data).

IT 697746-17-1P 697746-20-6P 697746-21-7P
697746-22-8P 697746-23-9P 697746-25-1P,
5-Naphthalen-1-ylimidazo[1,5-a]pyridine 697746-26-2P,
5-Biphenyl-4-ylimidazo[1,5-a]pyridine 697746-27-3P,
5-Biphenyl-2-ylimidazo[1,5-a]pyridine 697746-28-4P,
5-Benzofuran-3-ylimidazo[1,5-a]pyridine 697746-29-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,5-a]pyridine derivs. for treatment of aldosterone synthase mediated diseases)

RN 697746-17-1 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-(1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697746-20-6 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-[1,1'-biphenyl]-4-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697746-21-7 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-[1,1'-biphenyl]-2-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697746-22-8 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-(3-benzofuranyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697746-23-9 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-imidazo[1,5-a]pyridin-5-yl-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697746-25-1 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 697746-26-2 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)



RN 697746-27-3 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-[1,1'-biphenyl]-2-yl- (9CI) (CA INDEX NAME)



RN 697746-28-4 CAPLUS
CN Imidazo[1,5-a]pyridine, 5-(3-benzofuranyl)- (9CI) (CA INDEX NAME)



RN 697746-29-5 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-imidazo[1,5-a]pyridin-5-yl-, phenylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:425345 CAPLUS
DOCUMENT NUMBER: 117:25345
TITLE: Animal growth promotion with aromatase inhibitors
INVENTOR(S): Elbrecht, Alexander; Yang, Yi Tien; Smith, Roy G.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 479570	A2	19920408	EP 1991-309027	19911002
EP 479570	A3	19921125		
R: CH, DE, FR, GB, IT, LI, NL				
US 5162337	A	19921110	US 1990-593439	19901005
CA 2052494	A1	19920406	CA 1991-2052494	19910930
JP 04311355	A	19921104	JP 1991-257928	19911004

PRIORITY APPLN. INFO.: US 1990-593439 A 19901005

AB Aromatase inhibitors which prevent the conversion of androgens to estrogens are administered to healthy animals or female prenatal, neonatal, and postnatal animals to enhance weight gain and feed efficiency. Advantage of the invention over the use of testosterone or anabolic steroids is that with the use of the aromatase inhibitors the meat produced does not contain exogenous hormones. Female rats were fed with a rodent chow containing 33.3 ppm of (±)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]-pyridine-HCl for 2 wks and a significant gain in body weight was observed

IT 102676-37-9
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(animal growth promotion by)

RN 102676-37-9 CAPLUS
CN Benzonitrile, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:101826 CAPLUS
DOCUMENT NUMBER: 114:101826
TITLE: Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease
AUTHOR(S): Browne, L. J.; Gude, C.; Rodriguez, H.; Steele, R. E.; Bhatnager, A.
CORPORATE SOURCE: Res. Dep., Ciba-Geigy Corp., Summit, NJ, 07901, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(2), 725-36
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:101826
GI



I

AB The preparation of 5-phenyl-5,6,7,8-tetrahydroimidazopyridine derivs. I (R = cyano, Br, CH2OH, Me, CO2H, CO2Et) and their evaluation as inhibitors for aromatase and estrogen production was described; the most potent aromatase inhibitor was (+)-I (R = cyano), i.e. fadrozole (CGS 16949A). The mol. structure-activity relationship was discussed.

IT 93178-59-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrogenation of)

RN 93178-59-7 CAPLUS

CN Benzenemethanol, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



IT 93178-58-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 93178-58-6 CAPLUS

CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:406507 CAPLUS

DOCUMENT NUMBER: 105:6507

TITLE: Substituted fused imidazole compounds as aromatase

inhibitors

INVENTOR(S): Browne, Leslie J.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
SOURCE: Eur. Pat. Appl., 105 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 165904	A2	19851227	EP 1985-810279	19850617
EP 165904	A3	19870909		
EP 165904	B1	19910410		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4617307	A	19861014	US 1984-622421	19840620
FI 8502399	A	19851221	FI 1985-2399	19850617
FI 80694	B	19900330		
FI 80694	C	19900710		
AT 62415	T	19910415	AT 1985-810279	19850617
IL 75546	A	19900118	IL 1985-75546	19850618
CS 268672	B2	19900411	CS 1985-4449	19850618
CA 1276633	C	19901120	CA 1985-484263	19850618
DK 8502776	A	19851221	DK 1985-2776	19850619
DK 170302	B1	19950731		
NO 8502474	A	19851223	NO 1985-2474	19850619
NO 162467	B	19890925		
NO 162467	C	19900110		
AU 8543857	A	19860102	AU 1985-43857	19850619
AU 589565	B2	19891019		
ZA 8504615	A	19860226	ZA 1985-4615	19850619
HU 37936	A2	19860328	HU 1985-2417	19850619
HU 202529	B	19910328		
ES 544344	A1	19870101	ES 1985-544344	19850619
RO 92583	B3	19871130	RO 1985-119210	19850619
SU 1433413	A3	19881023	SU 1985-3917403	19850619
JP 61012688	A	19860121	JP 1985-133167	19850620
JP 04007746	B	19920212		
DD 237510	A5	19860716	DD 1985-277587	19850620
PL 145087	B1	19880831	PL 1985-254099	19850620
PL 145103	B1	19880831	PL 1985-259303	19850620
PL 145104	B1	19880831	PL 1985-259306	19850620
PL 145105	B1	19880831	PL 1985-259307	19850620
PL 145348	B1	19880930	PL 1985-259304	19850620
PL 145814	B1	19881130	PL 1985-259305	19850620
US 4728645	A	19880301	US 1986-825830	19860204
ES 555541	A1	19871116	ES 1986-555541	19860530
ES 555540	A1	19871216	ES 1986-555540	19860530
ES 555538	A1	19880316	ES 1986-555538	19860530
ES 555542	A1	19880316	ES 1986-555542	19860530
ES 555539	A1	19880401	ES 1986-555539	19860530
SU 1436878	A3	19881107	SU 1986-4027754	19860702
SU 1436879	A3	19881107	SU 1986-4027755	19860702
SU 1436880	A3	19881107	SU 1986-4027757	19860702
SU 1443802	A3	19881207	SU 1986-4027758	19860702
SU 1482530	A3	19890523	SU 1986-4027756	19860702
CS 268684	B2	19900411	CS 1986-8018	19861105
CS 268685	B2	19900411	CS 1986-8019	19861105
CS 268686	B2	19900411	CS 1986-8020	19861105
CS 268687	B2	19900411	CS 1986-8021	19861105
CS 268688	B2	19900411	CS 1986-8022	19861105
US 4889861	A	19891226	US 1987-120283	19871113
FI 8802863	A	19880615	FI 1988-2863	19880615
FI 83079	B	19910215		

FI 83079	C	19910527			
US 5428160	A	19950627	US 1990-632584		19901221
PRIORITY APPLN. INFO.:			US 1984-622421	A	19840620
			US 1982-451902	A2	19821221
			EP 1985-810279	A	19850617
			FI 1985-2399	A	19850617
			CS 1985-4449	A3	19850618
			US 1985-747195	A1	19850620
			US 1986-825830	A3	19860204
			US 1987-120283	A1	19871113
			US 1989-419922	B1	19891011

OTHER SOURCE(S): CASREACT 105:6507; MARPAT 105:6507

GI



I II

AB Aromatase-inhibiting imidazo[1,5-a]pyridines I [R1 = H, (un)substituted alkyl, NO2, halogen, OH, SH, (un)substituted NH2, SO3H, CHO, C2-20 acyl, CO2H, etc.; R2 = H, (un)substituted alkyl, halogen, OH, SH, CO2H, acyl, etc.], their 7,8-dihydro derivs.; and fused imidazoles II (R1 and R2 as before; n = 0-4), their stereoisomers, or salts, useful in treating aromatase-related diseases such as gynecomastia and breast cancer, were prepared The compds. inhibit the metabolic conversion of androgens to estrogens by prohibiting the cleavage of the cholesterol side chain. Thus, 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (III) was prepared by reaction of 5-(p-carboxyphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in C2H4Cl2 and concentrated H2SO4, followed by addition of HN3. A tablet was formulated containing III 10, lactose 253.5, corn starch 12.5, PEG 6000 15, Mg stearate 4 mg and water q.s.

IT 93178-71-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of)

RN 93178-71-3 CAPLUS

CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 102676-36-8
RL: PROC (Process)

(conversion of, to nitrile)
RN 102676-36-8 CAPLUS
CN Benzamide, N-(1,1-dimethylethyl)-4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



IT 102676-42-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to butylamide)
RN 102676-42-6 CAPLUS
CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



IT 93178-58-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 93178-58-6 CAPLUS
CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl-, ethyl ester (9CI) (CA INDEX NAME)



IT 93178-59-7P 93178-60-0P 102676-36-8P
102676-37-9P 102676-59-5P 102676-91-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as aromatase inhibitor)

RN 93178-59-7 CAPLUS
CN Benzenemethanol, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 93178-60-0 CAPLUS
CN Benzaldehyde, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 102676-36-8 CAPLUS
CN Benzamide, N-(1,1-dimethylethyl)-4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 102676-37-9 CAPLUS
CN Benzonitrile, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 102676-59-5 CAPLUS
CN Benzamide, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 102676-91-5 CAPLUS
CN Benzonitrile, 4-imidazo[1,5-a]pyridin-5-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:630526 CAPLUS
DOCUMENT NUMBER: 101:230526
TITLE: Imidazo[1,5-a]pyridines
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59118785	A	19840709	JP 1983-240012	19831221
JP 04007348	B	19920210		
US 4588732	A	19860513	US 1982-451902	19821221
EP 114573	A1	19840801	EP 1983-810596	19831215
EP 114573	B1	19880420		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 33651	T	19880515	AT 1983-810596	19831215
FI 8304665	A	19840622	FI 1983-4665	19831219
FI 78089	B	19890228		
FI 78089	C	19890612		
ES 528181	A1	19860901	ES 1983-528181	19831219
IL 70485	A	19870227	IL 1983-70485	19831219
CA 1250845	A1	19890307	CA 1983-443590	19831219
DK 8305864	A	19840622	DK 1983-5864	19831220
DK 160763	B	19910415		
DK 160763	C	19910930		
NO 8304711	A	19840622	NO 1983-4711	19831220
NO 161319	B	19890424		
NO 161319	C	19890802		
AU 8322703	A	19840628	AU 1983-22703	19831220
AU 576484	B2	19880901		
ZA 8309439	A	19840725	ZA 1983-9439	19831220
US 4728645	A	19880301	US 1986-825830	19860204
CS 268686	B2	19900411	CS 1986-8020	19861105
CS 268688	B2	19900411	CS 1986-8022	19861105
US 4889861	A	19891226	US 1987-120283	19871113
US 5428160	A	19950627	US 1990-632584	19901221

PRIORITY APPLN. INFO.:

US 1982-451902	A	19821221
EP 1983-810596	A	19831215
US 1984-622421	A2	19840620
CS 1985-4449	A3	19850618
US 1985-747195	A1	19850620
US 1986-825830	A3	19860204
US 1987-120283	A1	19871113
US 1989-419922	B1	19891011

OTHER SOURCE(S): CASREACT 101:230526

GI



AB Title compds. I (R = H, halo, alkyl, alkoxy, OH, arylalkoxy; R1 = H, halo, alkyl; R2 = carboxy, alkoxycarbonyl, carbamoyl, cyano, formyl, CH2OH, 5-tetrazolyl, 4,5-dihydro-2-oxazolyl, hydroxycarbamoyl; Z = vinylene, bond; Z1 = alkylene, alkynylene, alkenylene, etc.), their 5,6,7,8-tetrahydro derivs. and their salts, useful as antithrombotics (no data), were prepared Thus, condensation of 5-formylimidazo[1,5-a]pyridine with (EtO)2P(O)CH2CH:CHCO2Et gave imidazopyridine II.

IT 93178-54-2P 93178-55-3P 93178-58-6P
93178-59-7P 93178-60-0P 93178-61-1P
93178-62-2P 93178-71-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 93178-54-2 CAPLUS

CN Benzenepropanoic acid, 4-imidazo[1,5-a]pyridin-5-yl-α-methylene-,

methyl ester (9CI) (CA INDEX NAME)



RN 93178-55-3 CAPLUS
CN Benzenepropanoic acid, 4-imidazo[1,5-a]pyridin-5-yl-α-methylene- (9CI) (CA INDEX NAME)



RN 93178-58-6 CAPLUS
CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl-, ethyl ester (9CI) (CA INDEX NAME)



RN 93178-59-7 CAPLUS
CN Benzenemethanol, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 93178-60-0 CAPLUS
CN Benzaldehyde, 4-imidazo[1,5-a]pyridin-5-yl- (9CI) (CA INDEX NAME)



RN 93178-61-1 CAPLUS
CN 2-Propenoic acid, 3-(4-imidazo[1,5-a]pyridin-5-ylphenyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 93178-62-2 CAPLUS
CN 2-Propenoic acid, 3-(4-imidazo[1,5-a]pyridin-5-ylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 93178-71-3 CAPLUS
CN Benzoic acid, 4-imidazo[1,5-a]pyridin-5-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d his

(FILE 'HOME' ENTERED AT 13:40:39 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:40:48 ON 08 FEB 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 31 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:41:29 ON 08 FEB 2007
L4 6 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.09	204.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.68	-4.68

STN INTERNATIONAL LOGOFF AT 13:42:10 ON 08 FEB 2007